No Data
No Data
TD Cowen Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $100
TD Cowen analyst Daniel Brennan maintains $Exact Sciences(EXAS.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 52.9% and a
Court Dismisses Exact Sciences' '781 Patent Infringement Claim Against Geneoscopy
Geneoscopy Continues Path Toward Commercialization of ColoSense, Bringing New Innovations in Gastrointestinal Health to Patients in Need Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests
Exact Sciences Earns 2024 Great Place To Work Certification
Award marks sixth consecutive year company has received prestigious distinction Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been
Analysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)
Guardant Health Slips as FDA Comments on Cancer Screening Test
Exact Sciences Patent Infringement Case Against Geneoscopy to Proceed
No Data
5060 : nobody cares clown
Sikander KHANOP 5060: Dear tell me one example where I was wrong.